MARKET

VIRX

VIRX

Viracta Therapeutics Inc
NASDAQ
0.5111
+0.0011
+0.22%
Opening 12:37 11/28 EST
OPEN
0.5355
PREV CLOSE
0.5100
HIGH
0.5356
LOW
0.5000
VOLUME
213.63K
TURNOVER
0
52 WEEK HIGH
2.850
52 WEEK LOW
0.4705
MARKET CAP
19.74M
P/E (TTM)
-0.4133
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at VIRX last week (1120-1124)?
Weekly Report · 1d ago
Weekly Report: what happened at VIRX last week (1113-1117)?
Weekly Report · 11/20 09:28
Viracta Therapeutics Inc: Current report
Press release · 11/18 01:11
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Viracta Therapeutics (VIRX) and Gossamer Bio (GOSS)
TipRanks · 11/14 08:30
Weekly Report: what happened at VIRX last week (1106-1110)?
Weekly Report · 11/13 09:26
RBC Capital Maintains Outperform on Viracta Therapeutics, Lowers Price Target to $6
Benzinga · 11/10 19:33
Continued Buy Rating for Viracta Therapeutics Amid Promising Drug Trials and Stable Financial Performance
TipRanks · 11/10 11:58
Viracta Therapeutics Inc: Quarterly report
Press release · 11/10 01:38
More
About VIRX
Viracta Therapeutics, Inc. is a precision oncology company focused on the treatment and prevention of virus-associated cancers. Its lead product candidate is an all-oral combination therapy of its investigational drug, nanatinostat, and the antiviral agent valganciclovir (Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label phase II basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II trial for the treatment of EBV+recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its Vecabrutinib is a selective, reversible, non-covalent inhibitor of Bruton's tyrosine kinase (BTK) and interleukin-2-inducible kinase (ITK). VRx-510 is its preclinical-stage PDK-1 inhibitor. It is also investigating in pre-clinical studies the use of its epigenetic drug candidate, nanatinostat.

Webull offers Viracta Therapeutics Inc stock information, including NASDAQ: VIRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VIRX stock methods without spending real money on the virtual paper trading platform.